Comparative guide · 5 min read

Niacin vs Red Yeast Rice for Cholesterol — and why neither replaces a statin

Updated 2026-05-19 · Reviewed by SupplementScore editors · No sponsorships

Both niacin and red yeast rice can lower LDL cholesterol, but the products you buy are very different from the products studied. Red yeast rice contains naturally occurring monacolin K, which is chemically identical to prescription lovastatin — meaning red yeast rice is a statin in unstandardised form. Niacin (vitamin B3) lowers LDL and triglycerides and raises HDL at gram-level doses, but high-quality outcome trials (AIM-HIGH, HPS2-THRIVE) failed to show cardiovascular event reduction when added to a statin, and the safety signal was unfavourable. For most people, neither is a sensible first-line choice; for those who genuinely cannot tolerate statins, both have a narrow role with real cautions.

The most important fact first. Red yeast rice products vary wildly in monacolin K content — some brands contain near-zero monacolin K (no LDL effect), others contain doses equivalent to 10–40 mg lovastatin (a prescription drug). Without third-party testing you don't know what dose you're taking. The EU now caps monacolin K supplement content at 3 mg per daily dose; the US market is unstandardised.

Quick verdict

Scenario	Better choice	Why
Confirmed CVD or high 10-year risk	Prescription statin, not a supplement	Outcome trials favour statins; supplements are not equivalent.
Statin-intolerant (myalgia) seeking trial	Discuss bempedoic acid / ezetimibe / PCSK9 with cardiology	Outcome-trial-supported, lower-myalgia options now exist.
Borderline LDL, no other risk factors, motivated for non-statin	Standardised red yeast rice (with monitoring)	Modest LDL reduction; standardised products only.
Hypertriglyceridemia with low HDL	Prescription icosapent ethyl / fibrates, not OTC niacin	Outcome data favour Rx options.
Lp(a) elevation	Discuss with lipidology	Niacin lowers Lp(a) but does not reduce events; PCSK9 inhibitors and new Lp(a)-specific agents are the trial space.
"Flushing" tolerance unknown	Neither without dose titration	Both can cause significant flushing or GI upset at therapeutic doses.

How they actually work

Mechanism — adipose lipolysis vs HMG-CoA reductase inhibition

Niacin (nicotinic acid; not nicotinamide) at gram-level doses inhibits adipose-tissue lipolysis, reduces hepatic VLDL secretion, lowers LDL and Lp(a), and raises HDL. It does so via GPR109A signalling and other mechanisms incompletely understood. The flushing side effect is prostaglandin-D2-mediated; aspirin 325 mg 30 minutes before a dose substantially reduces flushing intensity.

Red yeast rice is fermented rice with Monascus purpureus mould; the active "monacolins" include monacolin K, chemically identical to lovastatin. Therefore red yeast rice is a statin — it inhibits hepatic HMG-CoA reductase the same way prescription statins do. Statin-class side effects (myalgia, transaminitis, rare rhabdomyolysis, possible new-onset diabetes) apply.

Evidence base by endpoint

LDL reduction: Niacin 1.5–3 g/day lowers LDL by 10–20%. Standardised red yeast rice with 5–10 mg monacolin K lowers LDL by 15–25%; the unstandardised market makes individual product performance unpredictable.
HDL: Niacin raises HDL by 15–25% (the biggest HDL effect of any lipid agent). Red yeast rice has minimal HDL effect.
Triglycerides: Niacin lowers triglycerides by 20–50%. Red yeast rice has modest TG effect (5–15%).
Lp(a): Niacin lowers Lp(a) by 20–30% — the only widely-available agent that does — but events were not reduced in outcome trials.
Cardiovascular events: The 1975 Coronary Drug Project showed niacin monotherapy reduced events in the pre-statin era. AIM-HIGH (2011) and HPS2-THRIVE (2014) added niacin to statins and found no incremental event reduction and worse adverse-event profiles. The contemporary view is that niacin does not reduce CV events on top of a statin.
Red yeast rice events: The China Coronary Secondary Prevention Study (Lu 2008) used a red yeast rice extract (Xuezhikang, a more standardised product) and showed cardiovascular event reduction — consistent with the statin mechanism. Generic OTC red yeast rice lacks comparable outcome data.

Practical rule. If your goal is event reduction (avoiding heart attacks and strokes), get prescription lipid management — statin, ezetimibe, or PCSK9 inhibitor per risk profile. If your goal is mild LDL lowering with a non-statin label, standardised red yeast rice is a statin at active doses and carries statin-class risks while sidestepping regulatory oversight. Niacin's role in 2026 is narrow — mainly for hypertriglyceridemia or Lp(a) where Rx options have failed, under specialist supervision.

Dose and form

Niacin: 500 mg titrating up to 1500–3000 mg/day in divided doses. Avoid "no-flush niacin" (inositol hexanicotinate) — it doesn't release free nicotinic acid and produces no meaningful lipid effect. Sustained-release niacin has elevated hepatotoxicity risk vs immediate-release. Start at 250 mg with food, take aspirin 325 mg 30 minutes prior to reduce flushing.

Red yeast rice: 600–1200 mg twice daily of a product standardised to a known monacolin K content. The EU 3 mg/day cap is a useful safety anchor; many US products exceed this without disclosure. Choose third-party-tested brands (USP, NSF, ConsumerLab) — and discuss with a clinician given the statin pharmacology.

Safety — taken seriously

Niacin: flushing (often intense; titrate), hepatotoxicity especially with sustained-release forms, hyperglycaemia (worsening of glycaemic control in pre-diabetes / T2DM), hyperuricaemia (gout flare), GI upset, and a small increase in serious infection signal in HPS2-THRIVE. Avoid in active liver disease, peptic ulcer disease, and uncontrolled diabetes.

Red yeast rice: statin-class adverse effects — myalgia, transaminitis, rare rhabdomyolysis, possible new-onset diabetes signal at higher doses. Drug interactions identical to lovastatin (CYP3A4 substrates — avoid concomitant strong inhibitors, grapefruit). Pregnancy / lactation contraindication. Citrinin contamination (a nephrotoxic mycotoxin) is a documented concern in unregulated products.

Cost

Generic niacin runs $0.10–0.30/day at therapeutic doses. Standardised red yeast rice runs $0.30–1.00/day. Generic prescription statins (atorvastatin, rosuvastatin) often cost $4–10/month with insurance — frequently cheaper than the supplement.

What we'd actually do

For elevated LDL with established CVD or high 10-year risk: prescription statin via primary care or cardiology. The outcome-trial weight is overwhelming and the cost is small.

For statin-intolerance: discuss bempedoic acid, ezetimibe, or PCSK9 inhibitor with cardiology — outcome data exist and tolerance profiles differ.

For mild LDL elevation with no other risk factors and patient preference against a statin label: dietary intervention (Mediterranean-style, plant-sterol-fortified foods), exercise, weight management, and a 12-week trial of a standardised red yeast rice product with baseline + 12-week LFTs and CK — recognising that this is statin pharmacology by another name.

Sources

AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255–2267. PMID: 22085343
HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203–212. PMID: 25014686
Lu Z, et al. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol. 2008;101(12):1689–1693. PMID: 18549841
Becker DJ, et al. Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med. 2009;150(12):830–839. PMID: 19528562
Cohen PA, et al. Variability in strength of red yeast rice supplements purchased from mainstream retailers. Eur J Prev Cardiol. 2017;24(13):1431–1434. PMID: 28641460
Canner PL, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8(6):1245–1255. PMID: 3782631